These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17053970)

  • 21. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
    Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
    Chagniel L; Robitaille C; Lebel M; Cyr M
    Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
    Picconi B; Gardoni F; Centonze D; Mauceri D; Cenci MA; Bernardi G; Calabresi P; Di Luca M
    J Neurosci; 2004 Jun; 24(23):5283-91. PubMed ID: 15190099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphorylation of Ca2+/calmodulin-dependent protein kinase type ii and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (ampa) receptor in response to a threonine-devoid diet.
    Sharp JW; Ross CM; Koehnle TJ; Gietzen DW
    Neuroscience; 2004; 126(4):1053-62. PubMed ID: 15207338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
    Wang XS; Zhang ZR; Zhang XR; Chen SY; Shao B; Xie CL
    Biomed Pharmacother; 2018 Nov; 107():769-776. PubMed ID: 30142538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
    Ahmed MR; Bychkov E; Kook S; Zurkovsky L; Dalby KN; Gurevich EV
    Exp Neurol; 2015 Apr; 266():42-54. PubMed ID: 25687550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
    Ohlin KE; Sebastianutto I; Adkins CE; Lundblad C; Lockman PR; Cenci MA
    Neuroimage; 2012 May; 61(1):228-39. PubMed ID: 22406356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of group I metabotropic glutamate receptors increases serine phosphorylation of GluR1 alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the rat dorsal striatum.
    Ahn SM; Choe ES
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1117-26. PubMed ID: 19258522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
    Smith CP; Oh JD; Bibbiani F; Collins MA; Avila I; Chase TN
    Neuropharmacology; 2007 Feb; 52(2):515-26. PubMed ID: 17116309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
    Brown AM; Deutch AY; Colbran RJ
    Eur J Neurosci; 2005 Jul; 22(1):247-56. PubMed ID: 16029214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
    Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
    Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
    Medhurst AD; Zeng BY; Charles KJ; Gray J; Reavill C; Hunter AJ; Shale JA; Jenner P
    Neuroscience; 2001; 105(2):353-64. PubMed ID: 11672603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
    Brannan T; Prikhojan A; Yahr MD
    Brain Res; 1998 Feb; 784(1-2):148-53. PubMed ID: 9518585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
    Nash JE; Brotchie JM
    Mov Disord; 2002 May; 17(3):455-66. PubMed ID: 12112191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arachidonic acid potentiates currents through Ca2+-permeable AMPA receptors by interacting with a CaMKII pathway.
    Nishizaki T; Matsuoka T; Nomura T; Enikolopov G; Sumikawa K
    Brain Res Mol Brain Res; 1999 Apr; 67(1):184-9. PubMed ID: 10101246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aniracetam metabolite 2-pyrrolidinone induces a long-term enhancement in AMPA receptor responses via a CaMKII pathway.
    Nishizaki T; Matsumura T
    Brain Res Mol Brain Res; 2002 Jan; 98(1-2):130-4. PubMed ID: 11834304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.